Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Clinical evaluation of ofloxacin in lower respiratory tract infections

Klinische Prüfung von Ofloxacin bei Infektionen der tiefen Atemwege

  • 21 Accesses

  • 10 Citations

Summary

The clinical efficacy and the safety of ofloxacin in lower respiratory tract infections were evaluated by 42 research groups in Japan. 127 patients with bacterial pneumonia and 399 patients with chronic lower respiratory tract infection were analyzed for clinical efficacy. The drug was orally administered, mostly in daily doses of 300 mg to 600 mg for an average of 15 days. The therapeutic success rate was 80% in bacterial pneumonias and 78% in chronic lower respiratory tract infections. As for bacteriological response, eradication rates of 93% and 72%, respectively, were observed against isolates from bacterial pneumonias and chronic lower respiratory tract infections. Side effects mainly in the gastrointestinal tract and central nervous system were noted in 7.6% of 540 patients, but none of them was severe.

Zusammenfassung

Die klinische Wirksamkeit und Sicherheit von Ofloxacin in der Behandlung von Infektionen der tiefen Atemwege wurde von 42 Forschergruppen in Japan geprüft. Bei 127 Patienten mit bakterieller Pneumonie und bei 399 Patienten mit chronischen Infektionen der tiefen Atemwege wurde die klinische Wirksamkeit von Ofloxacin untersucht. Das Medikament wurde oral verabreicht, die Dosierung lag in den meisten Fällen zwischen 300 und 600 mg Ofloxacin pro Tag; die Behandlungsdauer betrug im Durchschnitt 15 Tage. 80% der Patienten mit bakterieller Pneumonie und 78% der Patienten mit chronischen Atemwegsinfektionen sprachen auf die Therapie an. 93% der Erreger bakterieller Pneumonien und 72% der von chronischen Infektionen der tiefen Atemwege isolierten pathogenen Keime wurden eliminiert. Bei 7,6% der insgesamt 540 behandelten Patienten traten Nebenwirkungen auf, vorwiegend von seiten des Gastrointestinaltraktes und Zentralnervensystems. In keinem Fall traten schwere Nebenwirkungen auf.

This is a preview of subscription content, log in to check access.

Literature

  1. 1.

    Matsumoto, K., Shishido, H., Takahashi, A., Harada, T., Sakamoto, T., Kaida, S., Watanabe, K. In vitro, pharmacokinetic and clinical studies of DL-8280, a new oxazine derivative. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 509–525.

  2. 2.

    Yamaguchi, K., Nakazato, H., Koga, H., Watanabe, K., Tomita, H., Tanaka, H., Kohno, S., Ito, N., Fujita, K., Shigeno, Y., Suzuyama, Y., Saito, A., Hara, K., Sugawara, K., Matsuse, M., Kaku, M., Hayashi, A., Mochida, C., Usui, T., Ikebe, A., Nakano, M., Oka, R., Okuno, K., Fujiwara, T., Sai, M., Ohmagari, H. Laboratory studies and clinical evaluation of DL-8280 to the patients with respiratory infections. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 487–508.

  3. 3.

    Saito, A., Kato, Y., Ishikawa, K., Tomizawa, M., Nakayama, I., Sato, K. Studies on DL-8280, a new pyridonecarboxylic acid derivative. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 150–162.

  4. 4.

    Takebe, K., Nakamura, T., Osonoi, T., Okamoto, K., Takahashi, S., Takahashi, E., Kawamura, K., Yoshida, S., Matsuhashi, A., Kitaoka, M., Murakami, S. Clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 163–172.

  5. 5.

    Satoh, S., Konishi, K., Nishioka, K., Satoh, Y., Tanno, Y., Hiwatari, N., Ida, S., Takishima, T. Clinical studies on DL-8280 in the treatment of respiratory infections. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 173–177.

  6. 6.

    Aonuma, S., Onuma, K., Watanabe, A., Sasaki, M., Oizumi, K., Konno, K., Nagai, K. In vitro antibacterial activity of DL-8280 and its therapeutic efficacy on respiratory tract infections. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 178–184.

  7. 7.

    Hayashi, I., Abe, T. Clinical studies on DL-8280 in chronic respiratory tract infections. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 185–188.

  8. 8.

    Aoyagi, T., Koizumi, Y. Clinical evaluation of DL-8280 for respiratory infectious diseases. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 189–192.

  9. 9.

    Adachi, M., Murayama, Y., Imataka, K., Takizuka, H., Nakano, M., Kawai, M., Okayama, K., Okui, S., Katsu, M. Experimental and clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 193–203.

  10. 10.

    Takeda, H., Niwayama, M., Iwanaga, M., Tanaka, Y., Wada, K., Morimoto, T., Kobayashi, T., Arakawa, M. Clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 204–208.

  11. 11.

    Aoki, N., Sekine, O., Usuda, Y., Yuasa, Y., Nitta, I., Wakabayashi, N., Hayashi, S., Watanabe, K. Clinical study of DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 209–213.

  12. 12.

    Suzuki, Y., Yamasaku, F. Clinical studies of DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 214–218.

  13. 13.

    Kanazawa, Y. Bacteriological and clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 219–224.

  14. 14.

    Saito, A., Shimada, J., Ohmori, M., Shiba, K., Yamaji, T., Ihara, H., Kaji, M., Okuda, S., Saigusa, M., Miyahara, T., Ueda, Y. Clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 225–238.

  15. 15.

    Ooi, S., Kumada, T., Totsuka, K., Yamaguchi, H. Clinical investigation of DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 239–242.

  16. 16.

    Nakagawa, K., Watanabe, K., Koyama, M., Iijima, F., Yokozawa, M. Basic and clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 243–258.

  17. 17.

    Yamaoka, S., Yamane, Y., Mashimo, K. Clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 259–262.

  18. 18.

    Nakamori, Y., Yoshimura, K., Nakatani, T., Chonabayashi, N., Tachibana, A., Nakata, K., Tanimoto, H., Nozawa, K. Clinical studies on DL-8280 in the respiratory tract infection. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 263–271.

  19. 19.

    Watanabe, K., Ikemoto, H. Clinical studies in respiratory infectious disease. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 272–276.

  20. 20.

    Shimada, K., Urayama, K., Inamura, T., Adachi, K. Micribiological and clinical evaluation of DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 277–280.

  21. 21.

    Higashi, F., Fukuzawa, T., Ebihara, Y., Arikawa, K., Takano, M., Numasa, S., Funatsu, Y. Clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 281–285.

  22. 22.

    Ishibashi, H., Okabe, K., Horiuchi, T., Miyamoto, Y., Kabe, J. Clinical evaluation of DL-8280 in RTI. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 286–293.

  23. 23.

    Kobayashi, H., Takamura, K., Takeda, H., Oshitani, H. Clinical studies of DL-8280 on respiratory tract infections. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 332–340.

  24. 24.

    Obana, M., Kobayashi, Y., Fujimori, I. Clinical study of DL-8280 in the field of internal medicine. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 341–347.

  25. 25.

    Shindo, K., Ito, A., Fukushima, K., Kaminaga, Y., Sato, Y., Sakiyama, N. Clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 348–352.

  26. 26.

    Odagiri, S., Ikeda, H., Suzuki, K., Murohashi, K., Kaneko, T. Clinical studies of DL-8280 in respiratory tract infections. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 353–367.

  27. 27.

    Fukaya, K. Clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 368–372.

  28. 28.

    Matsumoto, F., Hojoh, T., Takahashi, T., Sugiura, E., Taura, Y., Hirabayashi, T. Bacteriological and clinical evaluation of DL-8280 in the field of respiratory and urinary tract infections. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 373–381.

  29. 29.

    Oyama, K., Shimizu, R. Clinical study of DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 382–389.

  30. 30.

    Kato, M., Nanjo, K., Kato, J., Kitaura, S., Yoshitomo, K., Yamamoto, M., Hanaki, H., Takeuchi, T., Yamamoto, T., Suzuki, K., Kishimoto, A. Laboratory and clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 390–399.

  31. 31.

    Abe, Y., Takahashi, M., Torikai, K. Clinical evaluation of DL-8280 in respiratory tract and urinary tract infections. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 400–403.

  32. 32.

    Maekawa, N., Nakanishi, M., Sakurai, N., Murakami, T., Lee, K., Marui, Y., Iwata, T., Amitani, R., Mochizuki, Y., Oida, K., Taguchi, Y., Inaba, N., Oda, Y., Uchihira, F., Hase, M., Tujino, H. Clinical studies on DL-8280 in the treatment of respiratory infections. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 404–413.

  33. 33.

    Miki, F., Takamatsu, K., Kohno, M. Bacteriological and clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 414–419.

  34. 34.

    Okamoto, Y., Maehara, K., Yonezu, S., Mase, K., Yoshioka, M., Yasunaga, K., Ueda, Y., Okubo, H. Laboratory and clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 420–435.

  35. 35.

    Taguchi, Y., Tanaka, E., Fujimoto, N., Mochizuki, Y., Amitani, R., Oida, K., Iwata, T. The usefulness of DL-8280 against chronic respiratory tract infections — mainly diffuse panbronchiolitis —. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 436–442.

  36. 36.

    Soejima, R., Niki, Y., Kawanishi, M., Matsushima, T., Kawane, H., Nakahama, C., Watanabe, M., Hino, J. Bacteriological and clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 443–453.

  37. 37.

    Kurimura, O., Sasaki, H., Aratani, Y., Kanetoh, E., Murai, T., Nozaki, K., Kosaka, T., Maruyama, T., Doi, H., Yokota, K., Shimonaka, A., Kono, M., Tamura, I. Laboratory and clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 454–461.

  38. 38.

    Ohguchi, H., Ueda, S., Nakagawa, M., Tamura, M., Tsubura, E. Clinical evaluation of DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 462–465.

  39. 39.

    Sawae, Y., Okada, K., Kumagai, Y., Yanase, T. Laboratory and clinical studies on DL-8280. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 466–477.

  40. 40.

    Tsurutani, H., Kishikawa, R., Yokota, T., Nagano, H. The effect of DL-8280 on infectious respiratory disease. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 478–486.

  41. 41.

    Sugimoto, M., Ando, M., Araki, S., Fukuda, Y., Tokunaga, K., Naoe, H. Clinical studies on DL-8280 in respiratory tract infection. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 526–528.

  42. 42.

    Nakayama, I., Kawamura, H., Kawaguchi, H., Ishiyama, S., Akieda, Y., Watanabe, T., Suzuki, T., Okada, T., Itokawa, K. Antibacterial activity and biliary excretion of DL-8280 and its clinical use in the field of surgery. Chemotherapy (Tokyo) 32, Suppl. 1 (1984) 822–842.

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kobayashi, H. Clinical evaluation of ofloxacin in lower respiratory tract infections. Infection 14, S279–S282 (1986). https://doi.org/10.1007/BF01661294

Download citation

Keywords

  • Success Rate
  • Gastrointestinal Tract
  • Clinical Evaluation
  • Family Medicine
  • Clinical Efficacy